Find out more about WaferiX technology
Novel sublingual wafer platform technology
Repurposed drugs have superior delivery and absorption, improved patient compliance and renewed market exclusivity.
Approved active compounds have established safety and toxicity profiles. We reposition these actives for new indications with unmet medical needs. Leveraging on expedited pathways like FDA 505(b)(2), development risks and costs are lowered with faster speed to market.
|
We develop innovative therapies that improve the quality of life for patients with pain, chronic diseases and debilitating conditions. |
We have a robust pipeline of CNS products that are being developed and clinically evaluated. Our portfolio includes Wafermine (sublingual ketamine) for pain and depression, BnoX (sublingual buprenorphine) for pain, and Wafesil (sublingual sildenafil) for erectile dysfunction.
Our lead product under development is a sublingual racemic ketamine wafer which is being evaluated for the treatment of acute moderate to severe pain.
Phase 3-ready, positive results in Phase 2b
Fully integrated from R&D, manufacturing, regulatory affairs to sales.
End-to-end service, faster speed to market
Fully licensed, cGMP facility.
Proprietary freeze-drying process supported by highly trained professionals and specialised equipment.
iX Biopharma Ltd has released the Notice of AGM and AGM Proxy Form for the upcoming Annual General Meeting of the company to be held on Friday, 16 October 2026 at 10.00am.
The Annual General Meeting will be held at 1A Science Park Drive, #01-21/22, Geneo, Nexus 2, Singapore 119314. The forms can be found in the link below.
Submission of AGM Proxy Form should be addressed to agm@ixbiopharma.com by no later than 10.00am on Tuesday, 13 October 2026.
Shareholders who wish to submit questions may do so via email to agm@ixbiopharma.com by no later than 10.00am on Wednesday, 7 October 2026.iX Biopharma Ltd has released the Notice of AGM and AGM Proxy Form for the upcoming Annual General Meeting of the company to be held on Friday, 16 October 2026 at 10.00am.
iX Biopharma Ltd has published both its Annual Report & Sustainability Report for FY2026. The respective reports can be found below.
iX Biopharma Ltd has released the auditor’s comment of accounts for the company.
More information can be found here.
iX Biopharma Ltd's corporate presentation at the 33rd CITIC Securities International Investor Forum in Hong Kong can be found here.
iX Biopharma Ltd is pleased to announce a major US regulatory development for Wafermine®, its sublingual ketamine wafer for moderate-to-severe acute pain.
The US Government has opened an emergency use pathway for drugs to treat moderate-to-severe acute pain in military casualties, clearing the way for the Company to advance its Wafermine® Emergency Use Authorization (EUA) submission to the FDA.
More information on the press release can be found here.
iX Biopharma Ltd has issued a notice of expiry of warrants.
For more information, please refer to the announcement here.
To exercise:
1. Complete and sign the form hcre in duplicate.
2. Prepare a bank draft or cashier’s order payable to “IX Biopharma Ltd”.
3. Submit both forms and payment to
Tricor Barbinder Share Registration Services,
9 Raffles Place, #26-01 Republic Plaza 1,
Singapore 048619
before 3:00 p.m. on any business day or before 5:00 p.m. on the expiration date (Fri, 17 July 2026).
The last day for trading in the Warrants on the Singapore Exchange Securities Trading Limited will be Friday, 10 July 2026, and trading will cease with effect from 9.00 a.m. on 13 July 2026.
iX Biopharma Ltd has announced the relocation of its manufacturing equipment to the United States
For more information, please refer to the company announcement here.
iX Biopharma Ltd has provided an update on the restructuring of its consumer business and proposed joint venture with Orion Specialty Labs
For more information, please refer to the company announcement here.
For years, we have advocated for ketamine’s potential in treating depression, particularly treatment-resistant depression. Today, the clinical reality is catching up.
The Institute of Mental Health (IMH) is now using intravenous ketamine successfully for patients with hard-to-treat depression, with more than half responding to treatment.
This is especially significant because racemic ketamine is not specifically approved to treat depression and is being used "off-label". Even though intravenous treatment requires a needle and multiple 40-minute infusions, clinicians are choosing ketamine because of the meaningful difference it can make. It shows that clinicians will adopt a treatment when the evidence and patient need support it.
The United States is already well ahead. Ketamine therapy is widely used in specialist clinics, and the US ketamine clinics market was estimated at US$3.77 billion in 2024.
At iX Biopharma, we recognized this potential years ago. Wafermine is our sublingual ketamine wafer - non-invasive, needle-free and designed to allow flexible dosing. While iX pursues its approval as a pain treatment, the IMH report reinforces ketamine’s broader therapeutic potential, including its off-label use for depression. Better delivery could broaden its impact.
This marks meaningful progress in addressing a significant unmet
need, as depression continues to affect a growing number of people.
